Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial

…, BH Brundage, LJ Rubin, FM Wigley… - Annals of internal …, 2000 - acpjournals.org
Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …

Joint injury in young adults and risk for subsequent knee and hip osteoarthritis

…, LA Mead, NY Wang, FM Wigley… - Annals of internal …, 2000 - acpjournals.org
Background: Knee and hip injuries have been linked with osteoarthritis in cross-sectional
and case–control studies, but few prospective studies have examined the relation between …

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

…, VM Hsu, P Carpentier, FM Wigley… - Annals of the …, 2011 - ard.bmj.com
Objectives Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc)
and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, …

A disease‐specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score

…, RF Spiera, LH Calabrese, FM Wigley… - Arthritis & …, 2001 - Wiley Online Library
Objective To refine and validate the Birmingham Vasculitis Activity Score (BVAS) as a
disease‐specific activity index for Wegener's granulomatosis (WG). Methods Sixteen members of …

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

FM Wigley, RA Wise, JR Seibold… - Annals of internal …, 1994 - acpjournals.org
Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered
intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. …

Raynaud's phenomenon

FM Wigley - New England Journal of Medicine, 2002 - Mass Medical Soc
A 37-year-old woman reports that her fingers turn blue when they are exposed to the cold
and that she has fatigue, arthralgias, and a history of small, painful digital ulcers. How …

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

…, B White, JR Seibold, FM Wigley… - Arthritis & …, 2002 - Wiley Online Library
Objective To document disease activity and functional status in patients with scleroderma (systemic
sclerosis [SSc]) and Raynaud's phenomenon (RP) and to determine the sensitivity to …

Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

…, J Ying, Y Han, SF Weng, CI Amos, FM Wigley… - Nature …, 2010 - nature.com
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and
internal organs that leads to profound disability and premature death. To identify new SSc …

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

B White, WC Moore, FM Wigley, HQ Xiao… - Annals of internal …, 2000 - acpjournals.org
Background: Lung inflammation (alveolitis) may cause lung fibrosis in scleroderma. Objective:
To determine whether cyclophosphamide treatment is associated with retention of lung …

Association of the autoimmune disease scleroderma with an immunologic response to cancer

…, AA Shah, AD Skora, LA Casciola-Rosen, FM Wigley… - Science, 2014 - science.org
Autoimmune diseases are thought to be initiated by exposures to foreign antigens that cross-react
with endogenous molecules. Scleroderma is an autoimmune connective tissue …